This article summarises some of the technical and regulatory challenges posed by next-generation sequencing technologies and the efforts being made to address them.
In the complex drug discovery process, one of the looming questions for any new compound is how it will be metabolised in a human body. While there are several methods for evaluating this, one of the most common involves CYP2D6, the enzyme encoded by the cytochrome P450-2D6 gene.
RNA-seq has revolutionised how scientists can interrogate gene expression. But after years of performing RNA-seq studies with short-read sequencers, many have realised that there is more to be discovered.
Next-generation sequencing has expanded the frontiers of genomic research, opening up new avenues of enquiry and offering insights into diverse areas of biology. Rapid developments in this field are dramatically lowering costs and increasing speeds.
Genomics has revolutionised the life sciences industry by combining human ingenuity with right-place/right-time serendipity. Advances in computer processing and storage have provided the bandwidth and throughput to enable the visionary science imagined by those pioneering the Human Genome Project.
While next-generation sequencing has revolutionised the way genomes are sequenced, this technology possesses a fundamental weakness - the inability to easily target specific regions of a genome. To address this, a method has been developed that uses biotinylated RNA 'baits' to fish targets out of a 'pond' of DNA fragments.
Human genetics is the foundation of disease as well as the response to pharmaceutical agents. Today, promising drugs are abandoned due to the lack of significant efficacy in broad patient populations. Recently, blockbuster drugs have been removed from the market due to unexplained toxicity not revealed in clinical trials.